Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 1;80(7):1792-1802.
doi: 10.1093/jac/dkaf171.

Liposomal amphotericin B prophylaxis in paediatrics: a systematic review

Emma V Thorley  1   2 , Jennifer Hatch  3 , Monica Li  3 , Sharlene N Mashida  2 , Elio Castagnola  4 , Alessio Mesini  4 , Thomas Lehrnbecher  5 , Andreas H Groll  6 , Adilia Warris  7 , Laura Ferreras-Antolin  1   2   7
Affiliations

Liposomal amphotericin B prophylaxis in paediatrics: a systematic review

Emma V Thorley et al. J Antimicrob Chemother. .

Abstract

Background: Liposomal amphotericin B (LAmB) is widely used for prophylaxis in paediatric patients at high risk of invasive fungal diseases (IFD) but its use is off-label and there is significant variability in dosage and frequency. This systematic review was conducted to evaluate the published data on prophylactic LAmB use in the paediatric population and to present the reported proportions of breakthrough IFD and the associated toxicity profile.

Methods: EMBASE, Medline, Web of Science and the Cochrane Database were systematically searched for primary research reporting on the use of LAmB as prophylaxis for IFD in the paediatric population up to 7 December 2023, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

Results: Twenty studies, comprising three clinical trials, 12 cohort studies, two point-prevalence surveys and three pharmacokinetic (PK) studies, with 2015 patients were included. A total of 717 cases presented individual patient data. Breakthrough IFD occurred in 7.2% (49/676). The most recognized side effects were hypokalaemia in 23.2% (125/538) and derangement of liver function tests in 15.0% (49/327). Discontinuation due to toxicity occurred in 6.0% (30/503) of patients. Of the four studies reporting PK data, two examined serum levels of LAmB, one analysed CSF levels and the remaining study peritoneal levels.

Conclusions: Despite widespread use of prophylactic LAmB, this systematic review highlights the paucity of paediatric data supporting its use. The heterogeneity observed in populations, dosing regimens and study design prevents conclusions being reached on its efficacy or the superiority of one dosing regimen. Overall, there is a clear need for further high-quality robust clinical data and targeted PK studies.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
PRISMA flow diagram. PRISMA flow diagram of included data sources [including results from both the original search date (11 November 2022) and the search re-run (07 December 2023)].
See this image and copyright information in PMC

References

    1. Pana ZD, Roilides E, Warris A et al. Epidemiology of invasive fungal disease in children. J Pediatr Infect Dis Soc 2017; 6: S3–11. 10.1093/jpids/pix046 - DOI - PMC - PubMed
    1. Groll AH, Pana D, Lanternier F et al. 8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation. Lancet Oncol 2021; 22: e254–69. 10.1016/S1470-2045(20)30723-3 - DOI - PubMed
    1. Ramos JT, Romero CA, Belda S et al. Clinical practice update of antifungal prophylaxis in immunocompromised children. Rev Espanola Quimioter Publicacion Of Soc Espanola Quimioter 2019; 32: 410–25. - PMC - PubMed
    1. EMA . Liposomal Amphotericin B Product-Specific Bioequivalence Guidance. European Medicines Agency (EMA), 2023. https://www.ema.europa.eu/en/liposomal-amphotericin-b-product-specific-b...
    1. FDA . AmBisome (Amphotericin B) Liposomal for Injection. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050740s021lbl.pdf

Publication types

MeSH terms